We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Major drivers of the growth include the projected launch of prophylactic options for the prevention of C. difficile, microbiological approaches for the treatment of recurrent CDIs